Abstract
Oral submucous fibrosis (OSMF) is considered a premalignant condition characterized by aggressive fibrosis of the submucosal tissues of the oral cavity reflecting its malignant transformation potential. Activation of transforming growth factor beta (TGF-beta) signaling has been reported to lead increased collagen production and fibrosis. Recently, significant upregulation of TGF-beta 1 has been reported in OSMF as compared to normal tissues. Therefore, inhibition of the TGF-beta 1 may pave for the development of therapeutics of OSMF. Based on the structure-assisted drug designing, we found "silmitasertib" as potent inhibitor of TGF-beta 1. We suggest that this molecule can be validated and implemented for the treatment of OSMF.